Clinical Trial

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Name: RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression — clinical trial record (NCT06420973)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.

Trial Details

NCT Number	NCT06420973
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Enrollment	54 participants
Start Date	2024-05-16
Primary Completion	2027-05-17 (estimated)
Study Completion	2027-09-17 (estimated)
Updated on ClinicalTrials.gov	2024-05-20